PATENT CLAIM ANALYSIS

Application Number: 16083408
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "007700"]

Abstract:
Disclosed is a highly efficient method for production of highly pure mutant-type human erythropoietin. The method is for production of mutant-type human erythropoietin, in which a transformed mammalian cell is allowed to produce the mutant-type human erythropoietin, and the supernatant of the culture is subjected to hydrophobic column chromatography, multimodal anion exchange column chromatography, anion exchange column chromatography, phosphate group affinity column chromatography, and gel filtration column chromatography, in this order.

Claim (Index 1):
A method for production of a mutant-type human erythropoietin comprising the amino acid sequence set forth as SEQ ID NO:2, the method comprising;\n (a) a step of providing a mutant-type human erythropoietin-producing mammalian cell which produces the mutant-type human erythropoietin, (b) a step of culturing the mutant-type human erythropoietin-producing mammalian cell in a serum-free medium to let the cell secrete the mutant-type human erythropoietin into the culture, (c) a step of preparing a supernatant by removing the cell from the culture, (d) a step of subjecting the supernatant to hydrophobic column chromatography to collect a fraction containing the mutant-type human erythropoietin, (e) a step of subjecting the fraction collected in the directly preceding step to multimodal anion exchange column chromatography to collect a fraction containing the mutant-type human erythropoietin, (f) a step of subjecting the fraction collected in the directly preceding step to anion exchange column chromatography to collect a fraction containing the mutant-type human erythropoietin, (g) a step of subjecting the fraction collected in the directly preceding step to column chromatography that employs a solid-phase material having affinity to phosphate group to collect a fraction containing the mutant-type human erythropoietin, and (h) a step of subjecting the fraction collected in the directly preceding step to gel filtration column chromatography to collect a fraction containing the mutant-type human erythropoietin, in this order.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 97.0
- Lexical Diversity: 1.90476
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15545194', '14416539', '14775248', '14352734', '14406192']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7647694849964682
- 35 USC 102 Novelty (BERT): 0.5077734219538413
- Combined Prediction Score: 0.7390698786922055
- Mean Citation Score: 254.364098
- Max Citation Score: 262.02765
- Similarity Product: 174.83107164150775

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test